Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks, Georgia, Dublin Beloud

@fool.com · 1 hour

Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks

Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks

Jazz Pharmaceuticals announced that its phase 3 clinical trial for the chemotherapy drug Zepzelca failed to meet its primary endpoint of overall survival in patients with second-line small-c...

Read more Fool.com